iTeos Therapeutics (ITOS) PT Lowered to $10 at Leerink Partners Jul 22, 2025 06:26AM
Concentra Biosciences to acquire iTeos Therapeutics for $10.047 per share Jul 21, 2025 07:30AM
Wedbush Downgrades iTeos Therapeutics (ITOS) to Neutral May 28, 2025 10:15AM
iTeos Therapeutics (ITOS) to Wind Down Operations May 28, 2025 08:32AM
iTeos Therapeutics (ITOS) Discontinues Belrestotug; PT Lowered to $12 at Piper Sandler May 14, 2025 07:45AM


May 13, 2025 01:48PM JPMorgan Downgrades iTeos Therapeutics (ITOS) to Neutral 'following the termination of iTeos’ partnered TIGIT program (belrestotug) this morning'
May 13, 2025 07:56AM iTeos Therapeutics (ITOS) GALAXIES Lung-201 of Belrestotug + Dostarlimab did not meet established criteria for clinically meaningful improvements in progression free survival
May 13, 2025 07:50AM iTeos Therapeutics (ITOS) Halted, News Pending
Apr 28, 2025 05:10PM iTeos Therapeutics, Inc. (ITOS) Tops Q1 EPS by 13c
Mar 6, 2025 07:26AM H.C. Wainwright Reiterates Buy Rating on iTeos Therapeutics (ITOS)
Jan 10, 2025 07:03AM iTeos Therapeutics (ITOS) Announces 2025 Strategic Priorities and Anticipated Milestones
Dec 13, 2024 07:18AM iTeos Therapeutics (ITOS) PT Lowered to $21 at H.C. Wainwright
Dec 12, 2024 08:56AM iTeos Therapeutics (ITOS) Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Nov 12, 2024 04:50PM iTeos Therapeutics, Inc. (ITOS) Tops Q3 EPS by 12c
Sep 18, 2024 05:38AM JPMorgan Reiterates Overweight Rating on iTeos Therapeutics (ITOS)
Sep 16, 2024 07:42AM Piper Sandler Reiterates Overweight Rating on iTeos Therapeutics (ITOS)
Sep 16, 2024 07:16AM iTeos Therapeutics (ITOS) Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab
Sep 16, 2024 07:13AM H.C. Wainwright Reiterates Buy Rating on iTeos Therapeutics (ITOS)
Sep 12, 2024 03:15PM iTeos Therapeutics (ITOS) call put ratio 9.4 calls to 1 put with focus on September 20 and 21 calls as share price up 14.9%
Aug 20, 2024 12:16PM Piper Sandler Reiterates Overweight Rating on iTeos Therapeutics (ITOS)
Aug 20, 2024 08:34AM iTeos Therapeutics (ITOS) Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at ESMO
Aug 13, 2024 06:24AM Wells Fargo Starts iTeos Therapeutics (ITOS) at Overweight
Aug 8, 2024 08:48AM iTeos Therapeutics, Inc. (ITOS) Tops Q2 EPS by 86c
Aug 5, 2024 07:00AM iTeos Therapeutics (ITOS) Announces Appointment of David Feltquate as Chief Medical Officer